Mar 31, 2023 5:52pm EDT bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results
Mar 28, 2023 8:00am EDT bioAffinity Technologies Announces Publication of Peer-Reviewed Paper on Proprietary Beads Used in CyPath® Lung for Noninvasive Detection of Early-Stage Lung Cancer
Mar 24, 2023 8:00am EDT bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023
Feb 13, 2023 8:00am EST bioAffinity Technologies Appoints Julie Anne Overton Director of Corporate Communications
Jan 24, 2023 8:00am EST bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research
Jan 04, 2023 8:00am EST bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments
Dec 15, 2022 8:30am EST bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench
Dec 01, 2022 8:00am EST bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting
Nov 14, 2022 7:30am EST bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update
Nov 10, 2022 8:15am EST bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory Board
